Dependence on Research Funding from Universities and Public Research Institutions
First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2023.
3 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Although sales channels to private companies, particularly overseas pharmaceutical companies, are currently expanding, future plans also assume sales to universities and public research institutions, and reductions in Grants-in-Aid for Scientific Research and other programs, or changes to those programs, could affect the performance of the Group.」
While expanding sales channels to private companies, the risk of dependence on universities, public research institutions, and public research funding is being reassessed. - FY2020RestatedAnnual report
「Although sales channels to private companies, particularly overseas pharmaceutical companies, are currently expanding, future plans also assume sales to universities and public research institutions, and reductions in Grants-in-Aid for Scientific Research and other programs, or changes to those programs, could affect the performance of the Group.」
While expanding sales channels to overseas pharmaceutical companies, the risk of dependence on universities, public research institutions, and public research funding continues. - FY2018RestatedAnnual report
「Although sales channels to private companies, particularly overseas pharmaceutical companies, are currently expanding, future plans also assume sales to universities and public research institutions, and reductions in Grants-in-Aid for Scientific Research and other programs, or changes to those programs, could affect the performance of the Group.」
Despite expanding sales channels to private companies, the risk of dependence on universities, public research institutions, and public research funding continues. - FY2017RestatedAnnual report
「Although sales channels to private companies, particularly overseas pharmaceutical companies, are currently expanding, future plans also assume sales to universities and public research institutions, and reductions in Grants-in-Aid for Scientific Research and other programs, or changes to those programs, could affect the performance of the Group.」
While indicating the expansion of sales channels to private companies, the disclosure continues to identify dependence on universities, public research institutions, and public research funding as a risk. - FY2016First statedAnnual report
「The universities and public research institutions that are the Group's major customers depend on public subsidies and grants, including Grants-in-Aid for Scientific Research, for most of their research funding. Although sales channels to private companies, particularly overseas pharmaceutical companies, are currently expanding, future plans also assume sales to universities and public research institutions.」
While noting the expansion of sales channels to private companies, the disclosure continues to identify dependence on sales to universities and public research institutions and on public funding programs.